Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
GENz-trials: Revolutionizing Clinical Trials to Optimize Assessment of Healthcare Innovations (GENz-trials)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Innovative Health Initiative
Action type: Research and Innovation actions
Partnership: IHI (JU-JTI)
Countries involved: Greece,Belgium,France,Italy,Netherlands,Cyprus,Bulgaria,Germany
Call: Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions (HORIZON-JU-IHI-2025-09-single-stage, 2025)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 14220000.0
EU funding (EUR): 7110000.0
Participants: 16
Project status: SIGNED

GENz-trials proposes a next-generation clinical trial framework that integrates data science, automation, and simulation technologies to transform how trials are designed, conducted, and evaluated. The strategy builds on three interlinked innovation pillars. i) Automation of critical trial workflows using generative AI for personalized informed consent, protocol drafting, monitoring, and regulatory submission, thereby reducing administrative burden and expediting trial initiation. ii) Artificial Intelligence (AI)-driven patient recruitment by analysing large-scale Electronic Health Records (EHRs), and real-world datasets to optimize matching between patients and trial protocols, improving enrolment rates, inclusiveness, and avoidance of patient dropout. iii) integration of Digital Twins (DTs) and Synthetic Control Arms (SCAs) for protocol optimization through in-silico simulation and enabling ethically sound alternatives to placebo groups, using real-world data to construct robust comparators with fewer enrolled participants. GENz-trials will serve as a platform for boosting innovation in the assessment of the added value of integrated healthcare solutions, providing a flexible and data-rich environment to evaluate not only pharmaceuticals, but also diagnostics, digital health tools, and therapeutic combinations, ultimately strengthening health technology assessment, regulatory decision-making, and reimbursement strategies. The GENz-trials framework will be unfolded in three phases: development of core tools; retrospective emulation of historical trials; and prospective validation through a Phase IV clinical equivalence trial comparing a generic anticoagulant with its branded counterpart. Through this phased strategy, GENz-trials aims to establish a more ethical, inclusive, and cost-effective paradigm for clinical research, accelerating the evaluation and deployment of life-saving healthcare innovations.

Keywords: synthetic control arms,artificial intelligence,clinical trials,emulation,clinical trials workflow optimization,hta,healthcare
Carbon-neutral, chemical-free, farm-level pulping of non-wood annual plants through our unique Fibers365 SteamFiber Technology (Fibers365)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Fibers365 GmbH was founded in 2020 by Stefan Radlmayr, Helge Leinich and Hermann Dauser and is based in Lenningen, Southern Germany. Our business model is based on the fast-growing market segment of renewable carbon and the distribution of at least CO2 neutral products. We produce highly sustainable paper fiber, pure lignin, 2nd gen sugar, and pure cellulose by using annually renewable plants and agricultural residues. Our mission is to conserve primeval forests and ecosystems. We aim to be a leader in scaling up pulping technology and building capacity to produce next generation solutions for paper, packaging and many other applications. We help protect the world's remaining primeval forests, but also enalbe restoring nature like marshlands, but nevertheless create value for the farmers by e.g. using paludiculture or other non-wood plants as feedstock material. We are the inventors of the patented Fibers365 SteamFiber technology. We see non-wood annual plants as the resource of the future and a key enabler for the production of new chemical-free cellulosic fibers, biopolymers and carbon neutral bioenergy. We are pioneering the competitive, carbon-neutral, chemical-free, farm-level pulping of non-wood annual plants through our exclusive Fibers365 SteamFiber Technology and a corresponding global brand and product strategy. Products from this process are virgin short fibre quality cellulosic fibre, lignin, 2nd generation sugars and process bio-energy. We have successfully proven that carbon-neutral and chemical-free pulping of non-wood annual plants can be competitive at significantly lower CAPEX and OPEX compared to traditional non-wood fibre pulping technologies. With the EIC grant and equity support, our solution will make a significant contribution to the European Green Deal as our unique SteamFiber process closes the soil fertility loop.

Keywords: fiber production,biomass,farm level pulping of non wood annual plants,co2 capture of biogenic emissions,carbon neutral,chemical free papermaking
Drug solution for bone fracture nonunions (OSTEOforUNION)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Croatia
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Bone fracture nonunion (FNU) is one of the leading unmet orthopaedic clinical needs, resulting in billions of healthcare costs annually without any drug approved by regulatory agencies for this debilitating indication. Due to considerable shortcomings of the current best practices in treating bone FNUs, patients are facing increased risks and morbidity. The market has available only bone substitutes and enhancers with limited clinical efficiency, highlighting an essential need for more effective therapies. Genera Research is on its way to filling the gap with its globally patented OSTEOGROW-C product: a novel biological drug transforming patients’ blood into bone. The proposed OSTEOforUNION project aims to develop and commercialize OSTEOGROW-C, an innovative drug for bone regeneration. OSTEOGROW-C is a novel treatment option for bone FNUs, an implant composed of an active substance - recombinant human bone morphogenetic protein 6 (rhBMP6) incorporated in an autologous blood coagulum (ABC) where tricalcium phosphate (TCP) ceramics is added as a compression resistant matrix (CRM). This combination forms a personalized implant that catalyzes bone growth at the implantation site. It is easily prepared in the operating room from the patient's blood without the need for a painful bone harvesting procedure, as in current treatment practices, with associated complications and morbidities (donor site pain, infection, nerve injuries, blood loss or iliac wing fracture etc.) and related additional healthcare costs. OSTEOGROW-C targets the global FNU market, which serves 6M patients yearly. Key overlapping markets are Fracture Fixation, Orthobiologics, Bone Grafts, and BMP. OSTEOGROW-C's unique stance promises to revolutionize the FNU market. The initial market entry will concentrate on the markets in the EU with 180.000 diagnosed long bone FNUs in Europe annually. Simultaneously, OSTEOGROW-C will be launched in the US, addressing more than 120.000 bone FNUs.

Keywords: biological drugs,bone fracture nonunions,biotechnology,healthcare system,medical devices,clinical trials,bone biology
Progressing Wave Energy Conversion via Large-Scale Additive Manufacturing (WEC-Pro)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-05-01
End date: 2027-04-30
Duration (months): 24.0
Total project cost (EUR): 193643.28
EU funding (EUR): 193643.28
Participants: 2
Project status: SIGNED

Wave energy conversion by harnessing untapped ocean resources has the potential to significantly expand the European renewable energy production and portfolio. However, high development costs, complex manufacturing processes, and low technology readiness levels have hindered the commercial scalability of wave energy converters (WECs). The WEC-Pro project seeks to address these challenges by leveraging cutting-edge Large-Scale Additive Manufacturing (LSAM) technologies to streamline the design, production, and testing of WECs. LSAM coupled with adapted optimization tools has the potential of reducing device’s costs by over 10 times. WEC-Pro will take advantage of the strong expertise of Politecnico di Torino in WECs optimization and Europe’s principal LSAM production centre, Caracol, to develop and adapting WEC modelling tools for LSAM application. For the use of the sustainable and fast LSAM, enabling the development of highly efficient and cost-effective devices, it is required to integrate new parameters in form of constrains to modelling tools. WEC-Pro’s primary goal is to integrate required LSAM parameters and upgrade established methods, design and optimization processes for WECs R&D scope. Key challenges of multi-parameter performance design, structural optimization, physical testing and LSAM production of WECS are addressed in three dedicated work packages, respectively. For demonstration, WEC-Pro covers two high-potential case study technologies, PivWEC (near-shore) and PeWEC (offshore), by testing for the first time fully-LSAM produced WECs physical models at Italy’s largest and most advanced Seakeeping tank (INSEAN, Rome). The planned outcomes include the development of open-source tools and models for WEC’s power absorption, structural optimization and data sets for LSAM-WECs benchmarking.

Keywords: marine renewable energy numerical modelling performance assessment additive manufacturing performance optimization structural analysis experimental testing rotating wec inertial wec
Active Mobility Innovations for Green and safe city sOlutionS (AMIGOS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Climate neutral and smart cities
Destination: Climate neutral and smart cities
Action type: Innovation actions
Countries involved: Germany,Bulgaria,Finland,Türkiye,Spain,Iceland,Latvia,Italy,Malta,France,Austria,Israel,Norway,Netherlands,Hungary,Romania
Call: Designing inclusive, safe, affordable and sustainable urban mobility (HORIZON-MISS-2022-CIT-01, 2022)
Start date: 2023-06-01
End date: 2027-05-31
Duration (months): 48.0
Total project cost (EUR): 10301351.25
EU funding (EUR): 9173068.51
Participants: 28
Project status: SIGNED

To reach carbon neutrality, cities must adopt new, more adapted energy models for urban mobility, relying on zero-emission and active mobility modes. The uptake of sustainable mobility solutions relies on their inclusivity, affordability and safety, as well as their consistency with users’ needs. Through co-creation activities and innovative digital tools, the AMIGOS project will identify present and future mobility challenges for 5 cities (living labs) and 10 urban areas (safety improvement areas). The digital tools include a Mobility Observation Box and an application for the collection of new mobility data, which will feed a big data platform for their analysis and digital twins to visualize mobility scenarios. They will allow urban stakeholders to identify mobility challenges and will serve as a basis for the co-development of adapted mobility solutions: towards reducing traffic, increasing public and active mobility modes, improving safety and co-habitation between different mobilities for the 5 cities, and towards increased safety for the 10 urban areas. Therefore, key stakeholders such as public authorities and vulnerable users will be included in the definition of technological and policy solutions mobility solutions which will be implemented in the cities. Their environmental, safety, economic and social impacts will be assessed, in addition to their medium- and long-term impact and their replicability, in view of their implementation in 5 twin cities.

Keywords: mobility,transportation,urban,city,co creation,inclusivity,active
Signaling decoded in ENhanCEr states – a molecular basis for plasticity in development and differentiation (SENCE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: Denmark
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Transcription is regulated by transcription factors (TFs) bound at enhancer elements located long-distances from the genes they regulate. How does this account for dynamic responses to the environment via signaling? Canonical views invoke signal induced changes in TF expression/modification or cofactor localization, but here we suggest that TF occupancy could be present before and after the signal, establishing competence, ensuring plasticity and blocking premature commitment. For ERK signaling, a central regulator of embryonic stem cell (ESC) differentiation, we found enhancers were regulated via selective recruitment of RNA Polymerase II (RNAPII) and associated cofactors. In this case, TFs do not play a direct role in enhancer regulation, but safeguard future activation in response to changes in signaling. In the context of developmental biology this paradigm could explain the dynamic nature of cell specification in the early mammalian embryo. In this proposal, we seek to understand enhancer specific regulation by ERK, exploit our ability to manipulate ERK to disentangle mechanism and focus on preimplantation development to explore how these phenomena explain plasticity. To circumvent heterogeneity created by feedback inhibition we developed a unique ESC line for cell intrinsic and synchronous ERK induction. We combine these ESCs with rapid TF degradation mutants to isolate homogeneous cell states that can be exploited to generate unique datasets and identify key factors within ERK response. We address how coactivator phosphorylation promotes selective recruitment of Mediator/RNAPII, explore the fundamental nature of enhancer activity and ask how uncoupling of transcriptional regulation from TF binding underpins developmental plasticity. By exploiting our capacity to modulate enhancer activity via signaling, we not only address how signaling regulates transcription to drive differentiation choices, but how enhancers themselves regulate gene expression.

Keywords: enhancers,pluripotency,pre implantation development,transcription,erk signaling,embryonic stem cells
Reactive fluids for intensified thermal energy conversion (REACHER)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Products and Processes Engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: France
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-04-01
End date: 2027-03-31
Duration (months): 60.0
Total project cost (EUR): 1436088.0
EU funding (EUR): 1436088.0
Participants: 2
Project status: SIGNED

Thermal engines, refrigeration systems and heat pumps rely on thermodynamic cycles, in which an inert working fluid converts input thermal and mechanical energies into another useful energy form (work or heat) by cyclically transforming its thermal energy content. Although the selection of the working fluid is the main lever to increase their performances, whatever the fluid is, recorded efficiencies remain far below the highest achievable ones. This deficiency is strongly affecting the exploitation of waste heat and renewable thermal energies by closed power cycles, as well as representing the main cause of the slow performance improvement of heat pumps and cooling technologies. With the aim to effectively increase the performances of thermodynamic cycles, I propose to investigate a radically new thermodynamic structure, resulting from the use of equilibrated reactive working fluids instead of inert ones. Preliminary calculations have indeed shown that the simultaneous conversion of the thermal and chemical energy of reactive fluids may result in the intensification of these energy conversion processes. This project applies an original methodology that integrates thermodynamic and kinetic predictive tools to discover and characterize suitable reactive fluids, allowing for the quantification of the effects of reaction features on cycle performance and the optimization of the cycle?s configuration. The novelty of such a solution approach and comprehensiveness of the applied methodology builds the innovative character of REACHER. Probably due to the complex multi-disciplinarity of the problem or to the negligence of this possible way to convert chemical energy in thermodynamic cycles, this field has remained substantially unexplored. The successful development of REACHER will provide the former fundamental understanding on how chemical energy can be efficiently exploited in the intensification of thermodynamic cycles for power, refrigeration and heating purposes.

Keywords: thermodynamic cycles reactive working fluids product design approach process design approach theoretical study and experimental observation
Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life course (OBESE-EMBRYO)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 1499998.0
EU funding (EUR): 1499998.0
Participants: 1
Project status: SIGNED

>50% of all pregnancies occur in couples with overweight or obesity, leading to tremendous risks for pregnancy and long-term offspring cardiovascular complications. My hypothesis is that an embryonic obesogenic environment, induced by the mother and father-to-be, predisposes to placental and embryonic programming of cardiovascular diseases across the life course. This leads to the intergenerational cycle of the cardiovascular disease epidemic. Lifestyle interventions in pregnancy are emerging, but unsuccessful in improving pregnancy or offspring cardiovascular outcomes due to inadequate timing, unclear intervention targets and unpredictable outcomes. OBESE-EMBRYO aims to radically improve care for overweight and obese parents-to-be by targeting the embryonic obesogenic environment to prevent development of cardiovascular diseases in offspring. To fulfil this mission, OBESE-EMBRYO will provide crucial insights for evidence-based, personalized, prevention and intervention strategies from preconception onwards. Beyond state-of-the-art aspects: 1) First population-based study on preconception and early-pregnancy as critical periods for adverse effects of an embryonic obesogenic environment, induced by the mother and father-to-be; 2) Intergenerational metabolism studies using metabolomics and oral-glucose-tolerance-tests to identify unknown metabolic pathways; 3) Cutting-edge imaging studies of cardiovascular development from embryonic life into adulthood to identify unknown developmental adaptations; 4) Longitudinal, repeated, placental-miRNA-studies throughout the first trimester, with an integrated approach to address replication, tissue specificity, functionality; 5) Translation of results into prediction models for offspring cardiovascular complications using Artificial-Intelligence and an evidence-based clinical support system for overweight and obese parents-to-be. Expected results will have great population impact on cardiovascular health in future generations.

Keywords: maternal and paternal obesity pregnancy developmental programming of cardiovascular diseases